Homepage
Technology
Our Tests
Ataraxis Breast
Overview
Recurrence Risk (RISK)
Chemotherapy benefit (CTX)
Neoadjuvant response (NEO)
Ataraxis Breast
About Us
News & Resources
Careers
Contact Us
Copyright © 2025, ataraxis.ai, All Rights Reserved.
Homepage
Technology
Our Tests
Ataraxis Breast
Overview
Recurrence risk (RISK)
Chemotherapy benefit (CTX)
Neoadjuvant response (NEO)
Ataraxis Breast
About Us
News & Resources
Careers
Ordering Portal
Contact Us
Ordering Portal
Contact Us
Ordering Portal
Ataraxis lands $20.4 million Series A to accelerate clinical deployment of AI precision medicine
Read More
May 28, 2025
Posters and Abstracts
ASCO 2025: Retrospective validation of a novel multimodal AI prognostic tool integrating digital pathology and clinical data against real world data and Oncotype DX in a Swiss breast cancer cohort.